Staidson’s STSP-0601 Begins Phase II Study for Hemophilia Treatment
China-based Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204) has announced the first subject dosing in...
Everest Medicines’ EVER206 Shows Positive Phase I Results in China
China-based Everest Medicines (HKG: 1952) has announced top-line results from a Phase I study in...
Bliss Bio Raises RMB 100 Million in Series B+ Financing for Oncology Pipeline
Hangzhou-based oncology-focused clinical-stage biotech Bliss Bio has reportedly raised over RMB 100 million (USD 14.7...
Junshi Biosciences’ Neotorch Study Achieves Superiority in Lung Cancer Trial
Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that its randomized, double-blind, placebo-controlled,...
Hengrui’s EZH2 Inhibitor SHR2554 Nears Breakthrough Therapy Designation
China-based Jiangsu Hengrui Pharmamceuticals (SHA: 600276) has announced that its enhancer for the zeste homolog...
Henlius Terminates TROP2 Antibody Licensing Deal with Chiome Bioscience
Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) has announced the termination of a licensing deal...
Structure Therapeutics Files for IPO on NASDAQ to Raise $119M
Structure Therapeutics Inc. (Nasdaq: GPCR), a Sino-US firm formerly known as ShouTi Inc., has filed...
Hansoh’s HS-10517 Greenlit for COVID-19 Clinical Study by NMPA
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving approval from the National...
Cowell Health Partners with Gilead Sciences to Enhance Drug Accessibility
Cowell Health has announced a partnership with US-based Gilead Sciences, Inc., (NASDAQ: GILD) aimed at...
IASO Bio Raises RMB 500 Million in Series C1 Funding for Cell Therapy Pipeline
China-based IASO Biotherapeutics has announced the completion of a nearly RMB 500 million (USD 73.7...
Junshi Biosciences’ COVID-19 Drug JT001 (VV116) Accepted for NMPA Review
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that its oral nucleoside analog drug...
Bristol-Myers Squibb’s Opdivo Gains New Indication for NSCLC Neoadjuvant Therapy in China
US-based pharmaceutical giant Bristol-Myers Squibb (BMS, NYSE: BMY) has secured another indication approval in China...
Daiichi Sankyo’s Mirogabalin Nears China Market Entry with CDE Review
Japan-based Daiichi Sankyo Inc. (TYO: 4568) has announced that China’s Center for Drug Evaluation (CDE)...
Bio-Thera’s Biosimilar BAT1806 Passes NMPA Review, Targets Roche’s Actemra
China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced that its biosimilar drug BAT1806, modeled after...
Abbisko’s ABSK021 Gains NMPA Approval for Phase II Study in cGVHD
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced receiving approval from the National...
AffaMed Secures China Rights to Eli Lilly’s Migraine Drug Galcanezumab
China-based AffaMed Therapeutics has announced an agreement with Eli Lilly and Company to obtain sole...
China’s NHC Releases Second National Drug Use Monitoring List
China’s National Health Commission (NHC) has released the second national drug use monitoring list, covering...
Suzhou Powersite Electric Secures Series B Funding for X-ray Imaging Expansion
China-based X-ray imaging core component supplier Suzhou Powersite Electric Co., Ltd has reportedly raised hundreds...
Beijing Interbio Secures Pre-Series A Funding for SPR Technology Expansion
Beijing Interbio Biology & Technology Co., Ltd, a China-based company specializing in surface plasmon resonance...
CStone’s RET Inhibitor Gavreto Approved in Taiwan for Lung and Thyroid Cancers
CStone Pharmaceuticals (HKG: 2616) has announced receiving marketing approval in Taiwan for its RET inhibitor...